Neil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared a post on X:
“2025 was a banner year for BC therapy across all subtypes. My take on the top practice-changing trials:
1. DESTINY-Breast09 | ASCO 2025
1L HER2+ MBC: TDxD + P vs THP. Median PFS 40.7 vs 26.9 months; HR 0.56. Regimen FDA-approved.
2. lidERA | SABCS 2025
Adjuvant ER+ BC: Giredestrant vs standard ET. Improved iDFS, HR 0.70.
3. monarchE (OS update) | ESMO 2025
High-risk ER+ BC: Abema + ET vs ET improved OS; HR 0.84.
4. DESTINY-Breast05 | ESMO 2025
High-risk HER2+ BC with residual disease: TDxD vs T-DM1 improved iDFS.
5. NeoCARHP | ASCO 2025
Neoadjuvant HER2+ BC: Carbo-containing vs carbo-free chemo demonstrated noninferior pCR.
6. HER2CLIMB-05 | SABCS 2025
1L HER2+ MBC: Tucatinib + HP maintenance vs HP alone improved PFS
7. TROPION-Breast02 | ESMO 2025
1L PD-L1- mTNBC: Dato-DXd vs chemo improved OS (23.7 vs 18.7 mo, HR 0.79).
8. ASCENT-04 | ASCO 2025
1L PD-L1+ mTNBC: Saci + pembro vs chemo + pembro improved PFS.
9. ASCENT-03 | ESMO 2025
1L PD-L1- mTNBC: Saci vs chemo improved PFS.
10. VIKTORIA-1 | ESMO 2025
2L ER+ MBC, PIK3CA WT: Geda + palbo + fulv triplet and geda + fulv doublet vs fulv improved PFS.
11. SERENA-6 | ASCO 2025
1L ER+ MBC switch: ctDNA-detected ESR1 mut; switch to camizestrant + CDK4/6i improved PFS vs AI + CDK4/6i.
12. DESTINY-Breast11 | ESMO 2025
Neoadjuvant HER2+ BC: TDxD + THP vs ddAC/THP improved pCR.”
More posts featuring Neil Vasan.